Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants코로나바이러스 질병 재조합 소단위 백신의 세 번째 용량으로 이종 부스팅은 다양한 중증 급성 호흡기 증후군 코로나바이러스 2 변이체에 대한 중화 항체 및 T 세포 면역을 증가시킵니다Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis Anti-RBD IgG anti-S booster vaccination CD4+ T cell components composite pattern coronavirus coronavirus disease COVID-19 COVID-19 vaccinations COVID-19 vaccine dose effective epitope Epitopes evaluated Evidence help Heterologous heterologous boosting homologous Humoral immunity Immune escape Immunity immunization strategy immunological in some inactivated Inactivated vaccine increase magnitude NAb NAbs natural infection Neutralizing Neutralizing antibodies neutralizing antibody neutralizing capacity omicron pandemic prime-boost strategy produced RBD IgG respiratory subunit Subunit vaccine Subunit vaccine. T cell T cell response T cells titre vaccination Vaccination strategies Vaccination strategy Vaccine Vaccine-induced immunity variant variants of concern waned [DOI] 10.1080/22221751.2022.2048969 PMC 바로가기 [Article Type] Article
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccinesCoronaVac 및 ChAdox1 nCov-19(AZD1222) 백신으로 이종 프라임-부스트 백신 접종 후 면역원성 및 반응성Article Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] 95% CI 95% confidence interval Administered age age and sex antibody assigned AZD1222 binding domain booster dose Care ChAdOx1 nCoV-19 Cohort cohorts Combination Concentration control group CoronaVac COVID-19 COVID-19 pandemic effective elicited enrolled finding geometric mean ratio GMR Health Heterologous heterologous prime-boost homologous immune response immunogenicity indicated mass participant primary endpoint prime-boost interval RBD reactogenicity robust Safe the median vaccination Vaccine vaccine administration vaccine combination. while [DOI] 10.1080/21645515.2022.2052525 PMC 바로가기 [Article Type] Article
Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variantsArticle Published on 2022-11-082022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] analysed B.1 B.1.617.2 BBIBP-CorV booster vaccination ChAdOx1-S Combination country COVID-19 elicited exhibited Gam-COVID-Vac greater Heterologous heterologous vaccination homologous immunized information mRNA-1273 mRNA-1273 vaccines Neutralizing Neutralizing antibodies non-replicative P.1 participant percentage Population protocol protocols provided SARS-CoV-2 second dose serum shortage significantly significantly lower vaccination Vaccination strategies Vaccination strategy Vaccine variant variants of concern. viral vector-based [DOI] 10.1016/j.vaccine.2022.10.021 PMC 바로가기
Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunityArticle Published on 2022-11-082022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] appear Bayesian Beta ChAdOx1 Clinical efficacy Correlate of protection COVID-19 D614G Delta Delta VOC distribution Efficacy ENhance evaluate Evaluating finding Heterologous highlight homologous Immunity inversion Mix-match mRNA-1273 neutralizing antibody omicron pandemic phase 3 trial predicted Predictive previous study provide ranged reduction reductions in strain vaccination Vaccine variant Variant of concern. variants variants of concern VoC VOCs was used while Wuhan [DOI] 10.1016/j.vaccine.2022.10.011 PMC 바로가기
High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of OmicronArticle Published on 2022-11-052022-11-16 Journal: BMC Infectious Diseases [Category] SARS, 변종, [키워드] 95% CI Admission caused Cohort cohort analysis COVID-19 COVID-19 hospitalization COVID-19 vaccines dose doses Effectiveness elderly Elderly cohort evaluated Follow-up hazard ratio Heterologous homologous Hospitalization ICU ICU treatment Immunity individuals intensive care omicron outcome protection reduced remained restored SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 Omicron variant severe COVID-19 vaccination Vaccine waned Waning vaccine effectiveness. [DOI] 10.1186/s12879-022-07814-4 PMC 바로가기
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trialArticle Published on 2022-11-012022-11-15 Journal: Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Administered adverse event approved assessment booster booster dose booster vaccination clinical trials Course COVID-19 COVID-19 vaccination COVID-19 vaccine cross-neutralization cross-neutralization. Day double-blind Effect fatigue Heterologous homologous humoral immunogenic immunogenicity incidence injection site pain Local Neutralizing antibodies neutralizing antibody outcome participant Participants Placebo placebo-controlled primary immunogenicity Randomized randomized placebo-controlled trial Recombinant spike protein reported robust Safe Safety safety profile saline placebo SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rate shown SpikoGen subunit the placebo group Trial Vaccine was performed [DOI] 10.1111/imm.13540 PMC 바로가기
The New SARS-CoV-2 Variants and Their Epidemiological Impact in MexicoArticle Published on 2022-10-262022-11-16 Journal: mBio [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome caused coronavirus COVID-19 COVID-19 disease COVID-19 pandemic Epidemiology evaluate example genomic genomic vigilance global pandemic help Heterologous Immunity Impact impacted Latin America mitigate New pandemic prevalent SARS-CoV-2 SARS-CoV-2 variants Surveillance the disease vaccination vaccination. variant variants virus Wuhan, China [DOI] 10.1128/mbio.01060-21 PMC 바로가기
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 VariantsArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome antibody AZD1222 booster vaccination cellular Cellular immune response cellular immune responses cellular immunity coronavirus COVID-19 Delta delta variant dose effective elevated elicit Emergency use authorization emerging variants evaluated Evidence Heterologous heterologous prime-boost heterologous vaccination humoral immune immune evasion immune response immune responses IMPROVE increase in induce Infection interferon mRNA mRNA vaccine mRNA-1273 Multiple Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody omicron Prevent priming promote Protein subunit protein subunit vaccine provided RBD Receptor binding domain reduced regimen response SARS-CoV-2 SARS-CoV-2 variants significantly subunit suggested T cell Taiwan vaccination vaccination schedule Vaccine variant variants Viral variants Viral variants. wild type [DOI] 10.1128/spectrum.00609-22 PMC 바로가기
‘Mix and Match’ vaccination: Is dengue next?Article Published on 2022-10-262022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 진단, [키워드] 'Mix and match' Antigen approach benefit boost breadth cellular Cellular responses Combination COVID-19 COVID-19 pandemic demonstrated Dengue dengue virus Dengvaxia dose effective Efficacy evaluated help Heterologous HIV homologous Human Humoral immunity Immunity immunization Impact Increased immunogenicity induce match overcome priming reactogenicity regimen reported response SARS-CoV-2 SARS-CoV-2 vaccine sequence severity significantly study participant T cell TAK-003 the vaccine Trial trials TV003 vaccination Vaccine vaccine. Vaccines [DOI] 10.1016/j.vaccine.2022.09.007 PMC 바로가기
Comparative Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Ferret ModelArticle Published on 2022-10-262022-11-15 Journal: mBio [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] acute respiratory syndrome Airborne transmission Analysis assessment Beta changes Comparative Contact coronavirus coronavirus 2 COVID-19 Critical Delta disease evaluate ferret ferrets genomic variant Heterologous highest histopathological homologous homologous or heterologous Human in vivo infection with SARS-CoV-2 inoculated lineages lowest Mild Model offered pandemic Particle pathogenicity provided Reinfection replicated Replication replication kinetics respiratory respiratory tract risk RNA SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strains SARS-CoV-2 variant Spread Strains Surveillance the spike protein the United State Transmissibility Transmission transmitted upper respiratory tract USA-WA1/2020 variant Variant. variants virulence virus virus virus infection virus load WA1 while [DOI] 10.1128/mbio.02421-22 PMC 바로가기